China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
WALTHAM, Mass., March 01, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
- Cowen and Company Annual Health Care Conference
Monday, March 6, 2017 at 2:40 p.m. ET
Location: Boston, MA
- Raymond James Annual Institutional Investors Conference
Wednesday, March 8, 2017 at 10:25 a.m. ET
Location: Orlando, FL
- Barclays Global Healthcare Conference
Tuesday, March 14, 2017 at 2:35 p.m. ET
Location: Miami, FL
To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of women's health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
